8-K: IN8bio's INB-619 Shows Strong Preclinical Autoimmune Data

IN8bio announced new preclinical data for its INB-619 T cell engager, demonstrating deep B cell depletion with a potentially superior safety profile for autoimmune diseases.

Summary

• IN8bio presented new preclinical data for its gamma-delta T cell engager (γδ-TCE) program, INB-619, at the 2025 American College of Rheumatology (ACR) Convergence Meeting.
• INB-619 achieved complete B cell depletion in preclinical systemic lupus erythematosus (SLE) donor models, demonstrating efficacy equivalent to FDA-approved CD19 and CD20 engagers, including blinatumomab and mosunetuzumab.
• The data showed minimal adverse cytokine release, such as IL-6, at concentrations multiples lower than the currently marketed compounds tested, suggesting a potentially superior safety profile.
• INB-619 is designed as the first pan-gamma delta T cell engager to significantly expand multiple γδ T cell subsets for efficient, durable target elimination.
• It achieved robust γδ T cell expansion and complete B cell depletion across both healthy donor samples and those with active SLE disease.
• INB-619 selectively expanded γδ T cells without activating CD4+ or CD8+ αβ T cells, supporting an improved safety and tolerability profile.
• The engager uniquely targets through the γδ-TCR and does not require CD3 engagement, which significantly reduces the potential for toxicities like Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANs).

Sentiment

Score: 8

Explanation: The preclinical data for INB-619 is highly positive, demonstrating equivalent efficacy to approved drugs with a potentially superior safety profile. This validates IN8bio's platform and opens significant therapeutic avenues in autoimmune diseases. The primary caution is that these are preclinical results, and clinical success is not guaranteed, along with general risks of capital raising and trial outcomes.

Positives

• INB-619 demonstrated equivalent efficacy to FDA-approved T Cell Engagers (blinatumomab and mosunetuzumab) in achieving complete B cell depletion.
• Showed minimal adverse cytokine release (e.g., IL-6) at concentrations multiples lower than marketed compounds, indicating a potentially superior safety profile.
• It is the first pan-gamma delta T cell engager designed to expand multiple γδ T cell subsets for durable target elimination.
• Achieved robust γδ T cell expansion and complete B cell depletion in both healthy and systemic lupus erythematosus (SLE) donor samples.
• Selectively expanded γδ T cells without activating CD4+ or CD8+ αβ T cells, supporting an improved safety and tolerability profile.
• Its unique targeting mechanism through the γδ-TCR, rather than CD3, significantly reduces the potential for toxicities like CRS and ICANs.
• Overcomes the limitation of low baseline γδ T cell counts that have hindered other γδ-TCE technologies in development.

Risks

• Risks to site initiation, clinical trial commencement, patient enrollment, and follow-up, as well as the company's ability to meet anticipated deadlines and milestones.
• Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio's product candidates.
• The risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations.
• IN8bio's ability to continue to operate as a going concern.
• The risk that IN8bio may not realize the intended benefits of its DeltEx platform.
• Uncertainty regarding the availability and timing of results from preclinical studies and clinical trials.
• Whether the outcomes of preclinical studies will be predictive of clinical trial results.
• Whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.
• The risk that trials and studies may be delayed and may not have satisfactory outcomes.
• Potential adverse effects arising from the testing or use of IN8bio's product candidates.
• The uncertainty of regulatory approvals to conduct trials or to market products.
• IN8bio's reliance on third parties, including licensors and clinical research organizations.

Future Outlook

INB-619 is positioned as a potential first-in-class, CD19-targeted, pan-gamma delta T cell engager. It is expected to allow for higher doses, enable deeper B cell depletion, and facilitate more durable immune modulation in complex autoimmune diseases. The company anticipates an improved safety and tolerability profile and believes INB-619 has the potential to transform the treatment of autoimmune diseases.

Management Comments

• "These results demonstrate IN8bio's unique know-how and capabilities with γδ T cell biology."
• "INB-619 is a γδ-TCE with innovative properties fully developed in-house."
• "We achieved deep, consistent B cell depletion, independent of starting γδ T cell levels, with a potentially superior safety profile compared with existing T cell engagers."
• "It's an important validation of our platform and its potential to address both cancer and autoimmune disease."

Industry Context

The biopharmaceutical industry is actively pursuing novel immunotherapies for autoimmune diseases, with a focus on targeted B cell depletion and improved safety profiles. Conventional T cell engagers often face challenges with toxicities like Cytokine Release Syndrome (CRS) and ICANs. IN8bio's INB-619, by leveraging gamma-delta T cells and a unique targeting mechanism, aims to differentiate itself by offering equivalent efficacy to existing FDA-approved compounds (like blinatumomab and mosunetuzumab) while significantly reducing adverse cytokine release, potentially setting a new standard for safety and efficacy in this therapeutic area.

Comparison to Industry Standards

• INB-619 demonstrated equivalent efficacy in B cell depletion to FDA-approved commercial T Cell Engagers (TCE) compounds, specifically blinatumomab (a CD19-targeted bispecific T cell engager approved for acute lymphoblastic leukemia) and mosunetuzumab (a CD20-targeted bispecific antibody approved for follicular lymphoma).
• INB-619 showed minimal adverse cytokine release, such as IL-6, at concentrations multiples lower than the currently marketed compounds tested, suggesting a potentially superior safety profile compared to these conventional TCEs.
• Unlike conventional T cell engagers that activate the CD3 receptor and can trigger toxicities like CRS and ICANs, INB-619 uniquely targets through the γδ-TCR, which significantly reduces the potential for such toxicities.

Stakeholder Impact

• Shareholders: Positive preclinical data could increase investor confidence and potentially lead to stock price appreciation, though tempered by the early stage of development and general risks.
• Patients with Autoimmune Diseases (e.g., SLE): Potential for a new, safer, and highly effective treatment option if INB-619 progresses successfully through clinical trials.
• Healthcare Providers: Could offer a novel therapeutic approach with a better safety profile for managing B cell-driven autoimmune disorders.
• Competitors: May face increased competitive pressure from IN8bio's innovative γδ-TCE platform.

Next Steps

• Further clinical development of INB-619 for autoimmune indications.
• Continued evaluation of INB-100 for acute myeloid leukemia.
• Continued evaluation of autologous DeltEx DRI T cells in combination with standard of care for glioblastoma in INB-200 and 400 programs.
• Advancing INB-600, novel γδ T cell engagers for potential oncology and autoimmune indications.

Key Dates

Recommendation

The preclinical data for INB-619 is exceptionally strong, demonstrating equivalent efficacy to FDA-approved T cell engagers while significantly reducing adverse cytokine release, suggesting a superior safety profile. This positions INB-619 as a potential first-in-class therapy for autoimmune diseases, validating IN8bio's proprietary gamma-delta T cell platform. While these are preclinical results and clinical trials carry inherent risks, the data provides a compelling de-risking event for the technology and opens up a large market opportunity. The potential for higher doses and deeper, more durable B cell depletion without severe toxicities represents a significant advancement. This positive development, coupled with the company's broader pipeline, makes IN8bio an attractive investment for long-term growth, warranting a 'buy' recommendation for investors with a higher risk tolerance for clinical-stage biopharmaceuticals.

Keywords

IN8bio, INAB, INB-619, gamma-delta T cell engager, autoimmune disease, systemic lupus erythematosus, SLE, B cell depletion, preclinical data, ACR Convergence Meeting, biopharmaceutical, T cell therapy, cytokine release syndrome, CRS, immunotherapy